Pacira Biosciences Inc expected to post earnings of 63 cents a share - Earnings Preview

Pacira Biosciences

29/04/2024 15:30

* Pacira Biosciences Inc  PCRX.OQ   PCRX.O  is expected
to show a
rise in quarterly revenue when it reports  results on May 1
(estimated) for the period ending March 31 2024
    * The Tampa Florida-based  company is expected to report a
3.5% increase in revenue to $165.88 million from $160.34 million
a year ago, according to the mean estimate from 9 analysts,
based on LSEG data.
    * ​LSEG's mean analyst estimate for Pacira Biosciences Inc
is for
earnings of 63 cents per share. 
    * The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 10 "strong buy" or "buy," no
"hold" and no "sell" or "strong sell."  
    * The mean earnings estimate of analysts had risen by
about 2.4%
in the last three months. ​
    * Wall Street's median 12-month price target for Pacira
Biosciences Inc is $45.00​, above​ its last closing price
of $26.33. ​​​

Previous quarterly performance (using preferred earnings measure
in US dollars). ​
 QUARTER       STARMINESM  LSEG IBES  ACTUAL    BEAT,   SURPRI
 ENDING        ARTESTIMAT  ESTIMATE             MET,    SE %
               E®                               MISSED  
 Dec. 31 2023  0.88        0.88       0.89      Beat    0.7
 Jan. 1 2023   0.77        0.78       0.72      Missed  -8.2
 Jun. 30 2023  0.77        0.76       0.78      Beat    2.9​
 Jan. 1 0001   0.62        0.62       0.53      Missed  -14.1
 ​​Dec.        0.82        0.83       0.80      Missed  -3.6
 31 2022                                                
 Sep. 30 2022  0.71        0.76       0.64      Missed  -16.2​
 Jan. 1 0001   0.81        0.85       0.51      Missed  -40.1
 Mar. 31 2022  0.80        0.83       0.64      Missed  -23.1
 This summary was machine generated April 29 at 14:30 GMT.  All
figures in US dollars unless otherwise stated. (For questions
concerning the data in this report, contact
Estimates.Support@lseg.com. For any other questions or feedback,
contact RefinitivNewsSupport@thomsonreuters.com)